跳至主要内容
临床试验/2022-502706-33-00
2022-502706-33-00招募中4 期

LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES

Grupo Espanol De Investigacion En Cancer De Mama64 个研究点 分布在 1 个国家目标入组 8,000 人开始时间: 2023年7月24日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
8,000
试验地点
64
主要终点
Dates of disease relapse (local, regional or distant) and second primary tumors. Event Free Survival (EvFS) in neoadjuvant studies. Event Free Survival (EFS) in adjuvant studies.

研究概览

简要总结

To describe the long-term evolution of the patients with invasive breast cancer in early stages included in GEICAM neoadjuvant and adjuvant clinical trials. Will be studied the frequency, type and location of the first relapse.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
性别
Female
接受健康志愿者

入选标准

  • Patients included in neoadjuvant and adjuvant clinical trials with GEICAM's participation. If any of these patients had taken part or is participating in another clinical trial, she/he is eligible for this trial and her/his information will also be collected.
  • Patients whose death or contact loss has not been previously collected in the databases of the original studies.

排除标准

  • Patients who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.

结局指标

主要结局

Dates of disease relapse (local, regional or distant) and second primary tumors. Event Free Survival (EvFS) in neoadjuvant studies. Event Free Survival (EFS) in adjuvant studies.

Dates of disease relapse (local, regional or distant) and second primary tumors. Event Free Survival (EvFS) in neoadjuvant studies. Event Free Survival (EFS) in adjuvant studies.

次要结局

  • Death date and whether or not it is related to breast cancer. Overall Survival (OS).

研究者

发起方
Grupo Espanol De Investigacion En Cancer De Mama
申办方类型
Patient organisation/association
责任方
Principal Investigator
主要研究者

Start Up Unit Manager

Scientific

Grupo Espanol De Investigacion En Cancer De Mama

研究点 (64)

Loading locations...

相似试验